{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T01:30:21Z","timestamp":1711675821822},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,28]]},"DOI":"10.7759\/cureus.57138","type":"journal-article","created":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T19:17:56Z","timestamp":1711653476000},"source":"Crossref","is-referenced-by-count":0,"title":["Exploring the Relationship of SARS-CoV-2 and Uric Acid Levels With a Focus on Gout Patients: A Scoping Review"],"prefix":"10.7759","author":[{"given":"Hemangi","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahi","family":"Basra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohit","family":"Muralidhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Demory Beckler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc M","family":"Kesselman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-022-06086-2","article-title":"Clinical outcomes of COVID-19 patients with rheumatic diseases: a retrospective cohort study and synthesis analysis in Wuhan, China","volume":"41","author":"Qi G","year":"2022","unstructured":"Qi G, Wang H, Guo Y, et al.. Clinical outcomes of COVID-19 patients with rheumatic diseases: a retrospective cohort study and synthesis analysis in Wuhan, China. Clin Rheumatol. 2022, 41:1899-910. 10.1007\/s10067-022-06086-2","journal-title":"Clin Rheumatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2017.04.008","article-title":"Gout: An old disease in new perspective - a review","volume":"8","author":"Ragab G","year":"2017","unstructured":"Ragab G, Elshahaly M, Bardin T. Gout: An old disease in new perspective - a review. J Adv Res. 2017, 8:495-511. 10.1016\/j.jare.2017.04.008","journal-title":"J Adv Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/art.41404","article-title":"Prevalence, incidence, and years lived with disability due to gout and its attributable risk factors for 195 countries and territories 1990-2017: a systematic analysis of the Global Burden of Disease Study 2017","volume":"72","author":"Safiri S","year":"2020","unstructured":"Safiri S, Kolahi AA, Cross M, et al.. Prevalence, incidence, and years lived with disability due to gout and its attributable risk factors for 195 countries and territories 1990-2017: a systematic analysis of the Global Burden of Disease Study 2017. Arthritis Rheumatol. 2020, 72:1916-27. 10.1002\/art.41404","journal-title":"Arthritis Rheumatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3121\/cmr.2023.1782","article-title":"Hyperuricemia and adverse outcomes in patients hospitalized for COVID-19 disease","volume":"21","author":"Feldman I","year":"2023","unstructured":"Feldman I, Natsheh A, Breuer GS. Hyperuricemia and adverse outcomes in patients hospitalized for COVID-19 disease. Clin Med Res. 2023, 21:87-94. 10.3121\/cmr.2023.1782","journal-title":"Clin Med Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11252","article-title":"Gout, rheumatoid arthritis, and the risk of death related to coronavirus disease 2019: an analysis of the UK Biobank","volume":"3","author":"Topless RK","year":"2021","unstructured":"Topless RK, Phipps-Green A, Leask M, Dalbeth N, Stamp LK, Robinson PC, Merriman TR. Gout, rheumatoid arthritis, and the risk of death related to coronavirus disease 2019: an analysis of the UK Biobank. ACR Open Rheumatol. 2021, 3:333-40. 10.1002\/acr2.11252","journal-title":"ACR Open Rheumatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes253","article-title":"Hospital admissions associated with gout and their comorbidities in New Zealand and England 1999-2009","volume":"52","author":"Robinson PC","year":"2013","unstructured":"Robinson PC, Merriman TR, Herbison P, Highton J. Hospital admissions associated with gout and their comorbidities in New Zealand and England 1999-2009. Rheumatology (Oxford). 2013, 52:118-26. 10.1093\/rheumatology\/kes253","journal-title":"Rheumatology (Oxford)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11495","article-title":"Characteristics and outcomes of people with gout hospitalized due to COVID-19: data from the COVID-19 Global Rheumatology Alliance physician-reported Registry","volume":"4","author":"Jatuworapruk K","year":"2022","unstructured":"Jatuworapruk K, Montgomery A, Gianfrancesco M, et al.. Characteristics and outcomes of people with gout hospitalized due to COVID-19: data from the COVID-19 Global Rheumatology Alliance physician-reported Registry. ACR Open Rheumatol. 2022, 4:948-53. 10.1002\/acr2.11495","journal-title":"ACR Open Rheumatol"},{"key":"ref8","unstructured":"Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases. a multicentric matched cohort study. (2023). Accessed: November 21, 2023: https:\/\/pubmed.ncbi.nlm.nih.gov\/32796045\/."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(23)00206-0","article-title":"Gout incidence and management during the COVID-19 pandemic in England, UK: a nationwide observational study using OpenSAFELY","volume":"5","author":"Russell MD","year":"2023","unstructured":"Russell MD, Massey J, Roddy E, et al.. Gout incidence and management during the COVID-19 pandemic in England, UK: a nationwide observational study using OpenSAFELY. Lancet Rheumatol. 2023, 5:622-32. 10.1016\/S2665-9913(23)00206-0","journal-title":"Lancet Rheumatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-021-05994-z","article-title":"Gout during the SARS-CoV-2 pandemic: increased flares, urate levels and functional improvement","volume":"41","author":"Garc\u00eda-Maturano JS","year":"2022","unstructured":"Garc\u00eda-Maturano JS, Torres-Ordaz DE, Mosqueda-Guti\u00e9rrez M, et al.. Gout during the SARS-CoV-2 pandemic: increased flares, urate levels and functional improvement. Clin Rheumatol. 2022, 41:811-8. 10.1007\/s10067-021-05994-z","journal-title":"Clin Rheumatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2022.135","article-title":"Incidence of rheumatic diseases during the COVID-19 pandemic in South Korea","volume":"38","author":"Ahn SM","year":"2023","unstructured":"Ahn SM, Eun S, Ji S, et al.. Incidence of rheumatic diseases during the COVID-19 pandemic in South Korea. Korean J Intern Med. 2023, 38:248-53. 10.3904\/kjim.2022.135","journal-title":"Korean J Intern Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejr.2023.08.003","article-title":"Coronavirus disease 2019 (COVID-19) infection in patients with rheumatic diseases: clinical characteristics and relation to anti-rheumatic therapy","volume":"45","year":"2023","unstructured":"Coronavirus disease 2019 (COVID-19) infection in patients with rheumatic diseases. clinical characteristics and relation to anti-rheumatic therapy. Egypt Rheumatol. 2023, 45:314-8. 10.1016\/j.ejr.2023.08.003","journal-title":"Egypt Rheumatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.3557","article-title":"Death due to COVID-19 in a patient with diabetes, epilepsy, and gout comorbidities","volume":"9","author":"Safdarian AR","year":"2021","unstructured":"Safdarian AR, Momenzadeh K, Kahe F, Farhangnia P, Rezaei N. Death due to COVID-19 in a patient with diabetes, epilepsy, and gout comorbidities. Clin Case Rep. 2021, 9:461-4. 10.1002\/ccr3.3557","journal-title":"Clin Case Rep"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00401-X","article-title":"Gout and the risk of COVID-19 diagnosis and death in the UK Biobank: a population-based study","volume":"4","author":"Topless RK","year":"2022","unstructured":"Topless RK, Gaffo A, Stamp LK, Robinson PC, Dalbeth N, Merriman TR. Gout and the risk of COVID-19 diagnosis and death in the UK Biobank: a population-based study. Lancet Rheumatol. 2022, 4:e274-81. 10.1016\/S2665-9913(21)00401-X","journal-title":"Lancet Rheumatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/art.42339","article-title":"Gout and excess risk of severe SARS-CoV-2 infection among vaccinated individuals: a general population study","volume":"75","author":"Xie D","year":"2023","unstructured":"Xie D, Choi HK, Dalbeth N, et al.. Gout and excess risk of severe SARS-CoV-2 infection among vaccinated individuals: a general population study. Arthritis Rheumatol. 2023, 75:122-32. 10.1002\/art.42339","journal-title":"Arthritis Rheumatol"},{"key":"ref16","article-title":"Omicron variant infection in inflammatory rheumatological conditions - outcomes from a COVID-19 naive population in Aotearoa New Zealand","volume":"1","unstructured":"Omicron variant infection in inflammatory rheumatological conditions - outcomes from a COVID-19 naive population in Aotearoa New Zealand. Lancet Regional Health. 1.2023.","journal-title":"Lancet Regional Health"},{"key":"ref17","unstructured":"Serum uric acid, disease severity and outcomes in COVID-19. (2023). Accessed. December 5, 2023: https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/s13054-021-03616-3."},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.12669\/pjms.38.8.6636","article-title":"Uric acid as a prognostic predictor in COVID-19","volume":"38","author":"Parmaks\u0131z E","year":"2022","unstructured":"Parmaks\u0131z E, Parmaks\u0131z ET. Uric acid as a prognostic predictor in COVID-19. Pak J Med Sci. 2022, 38:2246-52. 10.12669\/pjms.38.8.6636","journal-title":"Pak J Med Sci"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-021-00745-2","article-title":"Association of serum uric acid levels with COVID-19 severity","volume":"21","author":"Hu F","year":"2021","unstructured":"Hu F, Guo Y, Lin J, Zeng Y, Wang J, Li M, Cong L. Association of serum uric acid levels with COVID-19 severity. BMC Endocr Disord. 2021, 21:97. 10.1186\/s12902-021-00745-2","journal-title":"BMC Endocr Disord"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.19193\/0393-6384_2022_1_113","article-title":"Uric acid and mortality relationship in COVID-19","volume":"725","author":"\u00c7eki\u00e7 D","year":"2022","unstructured":"\u00c7eki\u00e7 D. Uric acid and mortality relationship in COVID-19. Acta Medica Mediterr. 2022, 725:731. 10.19193\/0393-6384_2022_1_113","journal-title":"Acta Medica Mediterr"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.633767","article-title":"Serum uric acid concentrations and risk of adverse outcomes in patients with COVID-19","volume":"12","author":"Chen B","year":"2021","unstructured":"Chen B, Lu C, Gu HQ, et al.. Serum uric acid concentrations and risk of adverse outcomes in patients with COVID-19. Front Endocrinol (Lausanne). 2021, 12:633767. 10.3389\/fendo.2021.633767","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref22","unstructured":"Association of serum calcium and serum uric acid level with inflammatory markers to predict the outcome of COVID-19 infection. a retrospective study. (2023). Accessed: December 5, 2023: https:\/\/www.jcdr.net\/article_abstract.asp?issn=0973-709x&year=2023&volume=17&issue=1&page=BC01&issn=0973-709x&id=17209."},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s11845-022-03265-7","article-title":"Outcomes of COVID-19 in people with rheumatic and musculoskeletal disease in Ireland over the first 2\u00a0years of the pandemic","volume":"192","author":"Conway R","year":"2023","unstructured":"Conway R, Nikiphorou E, Demetriou CA, et al.. Outcomes of COVID-19 in people with rheumatic and musculoskeletal disease in Ireland over the first 2\u00a0years of the pandemic. Ir J Med Sci. 2023, 192:2495-500. 10.1007\/s11845-022-03265-7","journal-title":"Ir J Med Sci"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2022.07.014","article-title":"U-shaped association between abnormal serum uric acid levels and COVID-19 severity: reports from the Japan COVID-19 Task Force","volume":"122","author":"Fukushima T","year":"2022","unstructured":"Fukushima T, Chubachi S, Namkoong H, et al.. U-shaped association between abnormal serum uric acid levels and COVID-19 severity: reports from the Japan COVID-19 Task Force. Int J Infect Dis. 2022, 122:747-54. 10.1016\/j.ijid.2022.07.014","journal-title":"Int J Infect Dis"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-021-03616-3","article-title":"Serum uric acid, disease severity and outcomes in COVID-19","volume":"25","author":"Dufour I","year":"2021","unstructured":"Dufour I, Werion A, Belkhir L, et al.. Serum uric acid, disease severity and outcomes in COVID-19. Crit Care. 2021, 25:212. 10.1186\/s13054-021-03616-3","journal-title":"Crit Care"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/225074-exploring-the-relationship-of-sars-cov-2-and-uric-acid-levels-with-a-focus-on-gout-patients-a-scoping-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T19:18:03Z","timestamp":1711653483000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/225074-exploring-the-relationship-of-sars-cov-2-and-uric-acid-levels-with-a-focus-on-gout-patients-a-scoping-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,28]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.57138","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,28]]}}}